Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024.
賓夕法尼亞州新希望,2024年11月26日(環球新聞網絡)-- Orchestra BioMed Holdings, Inc.(納斯達克:OBIO,"Orchestra BioMed"或"公司"),一家通過風險回報共享合作伙伴關係加速高影響力技術向患者提供的生物醫藥公司,今天宣佈公司管理層將在2024年12月3日至5日在紐約舉行的派傑投資第36屆年度醫療會議上進行演講,並可進行一對一會議。
Details of the presentation are shown below.
以下是演示的詳細信息。
Format: Fireside Chat
Date: Wednesday, December 4, 2024
Time: 3:00 PM EST
Webcast:
格式:爐邊聊天
日期:2024年12月4日星期三
時間:下午3:00 東部標準時間
網絡直播:
A replay of the webcast will be available on the Events section of the Orchestra BioMed website for 90 days following the presentation.
演示的網絡廣播回放將在樂隊生物醫療網站的活動部分提供,持續90天。
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit , and follow us on LinkedIn.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed's partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed's lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIm therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAb for the treatment of artery disease. For further information about Orchestra BioMed, please visit , and follow us on LinkedIn.
References to Websites and Social Media Platforms
有關網站和社交媒體平台的引用信息的參考資料不構成包含在此類網站或社交媒體平台上的信息的引用,並且您不應將此類信息視爲本新聞稿的一部分。
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
關於高血壓及起搏器患者高血壓風險
Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
484-682-4892
Kkirkellis@orchestrabiomed.com
聯繫方式:
凱爾西·柯克-埃利斯
樂團生物醫學
484-682-4892
Kkirkellis@orchestrabiomed.com
譯文內容由第三人軟體翻譯。